What is the impact of dual blockade versus monotherapy on all-cause mortality in patients with CKD with and without diabetes?
Two of these studies excluded participants with There was no significant difference in all-cause mortality from dual blockade versus monotherapy in 7 studies of 16,862 patients with a mean follow-up of 3.4 years. However, a traditional pair-wise meta-analysis performed by the ERT demonstrated harm for dual blockade compared to monotherapy. In studies of patients with CKD with and without diabetes, dual blockade compared to mon- otherapy caused a slightly higher risk of all-cause mortality of borderline significance (HR: 1.09; 95% CI: 1.00 1.20) based on data from 10,615 patients in 4 studies with a mean follow-up of and (Supplementary Table S31).